top cx logo
cx logo
Explorearrow down
search icon
arrow down

Health authorities withdraw cough syrups in France due to allergy risk

The syrups which are based on pholcodine will no longer be sold. However, no immediate action is required if you have taken the medicine

A photo of a woman coughing intensely

The syrups are used to treat dry or irritating coughs, but they have been recalled due to a risk of developing an allergy later on Pic: / Shutterstock

Four cough syrups in France have been withdrawn from sale due to a “severe risk” of allergies, health authorities have confirmed.

Medicines safety agency L’Agence nationale de sécurité des médicaments et des produits de santé (ANSM) has taken the action over the syrups which are based on pholcodine as this can later cause an allergy risk when taken before a medicine used in general anaesthetic.

In a statement, it said: “Syrups based on pholcodine are used to calm dry coughs and irritation coughs in adults and children aged over 30 months and weighing more than 15kg.”

It said that it had withdrawn the syrups because “taking one of these medicines exposes people to developing an allergy towards curare, which is used during general anaesthetic, even if the anaesthetic is being given several weeks after taking the [cough] medicine”.

The syrups being recalled are:  

  • Di­mé­tane sugar-free 133 mg/100 ml, syrup (Bio­co­dex)
  • Bio­ca­lyp­tol 6.55 mg/5 ml sugar-free syrup, coloured with saccharin sodium and liquid maltitol (Zam­bon)
  • Bio­ca­lyp­tol, syrup (Zam­bon)
  • Phol­co­dine Bio­ga­ran 6.55 mg/5 ml, syrup (Bio­ga­ran)

The ANSM said: “Due to these new data, given the non-essential nature of these syrups and the existence of therapeutic alternatives, we consider that their benefit/risk ratio is unfavourable.

“As a result, we will suspend [their market authorisation] and perform a recall on all of these syrups at the start of September.”

Anyone who is using, or has used, a syrup based on pholcodine, is safe and there is “currently no particular action to take”, the ANSM said. However, it advised that “if you are later required to go under general anaesthetic, the anaesthetist may ask you if you have consumed this type of syrup”.

People are also invited to register on the Mon espace santé website, and indicate that you have taken a medicine based on pholcodine. 

Health professionals have also been issued with recommendations to help minimise the risk. Medicines based on pholcodine will now pass to a prescription-only basis and doctors must communicate the risks.

The ANSM said it had been monitoring these syrups for several years before making the decision to take them off the market. 

It said that its decision was also based on a European benefit-risk evaluation, following rising reports of anaphylaxis (severe allergic reaction) in France, and the publication of relevant studies in Norway and Sweden.

Related articles

‘Medicines to avoid in 2022’ list published by French medical review 

Boxes of anti-anxiety drug recalled in France over incorrect leaflet

Resident or second-home owner in France?
Benefit from our daily digest of headlines and how-to's to help you make the most of life in France
By joining the newsletter, you agree to our Terms & Conditions and Privacy Policy
See more popular articles
The Connexion Help Guides
featured helpguide
Healthcare in France*
Featured Help Guide
- Understand the French healthcare system, how you access it and how you are reimbursed - Useful if you are new to the French healthcare system or want a more in-depth understanding - Reader question and answer section Aimed at non-French nationals living here, the guide gives an overview of what you are (and are not) covered for. There is also information for second-home owners and regular visitors.
Get news, views and information from France
You have 2 free subscriber articles left
Subscribe now to read unlimited articles and exclusive content
Already a subscriber? Log in now